

Anti-osteoarthritis effects of Pomegranate, *Eucommiae* cortex and *Achyranthis radix* extracts on the primary cultured rat articular chondrocytes

Beom-Rak Choi^{1,2)*}, Sae-Kwang Ku^{3,4)*}, Su-Jin Kang^{4,5)}, Hye-Rim Park¹⁾,
Mi-Sun Sung¹⁾, Young-Joon Lee^{4,5)**} & Ki-Moon Park^{2)**}

¹⁾Research Institute, HL Science Co., Ltd.,

²⁾Department of Foodscience and biotechnology, Sungkyunkwan University

³⁾Department of Histology and Anatomy, College of Korean Medicine, Daegu Haany University

⁴⁾The Medical Research Center for Globalization of Herbal Medicine, Daegu Haany University

⁵⁾Department of Preventive Medicine, College of Korean Medicine, Daegu Haany University

Abstract

Objectives : The objective of present study is to evaluate anti-arthritic effects of dried pomegranate concentrate powders (PCP), *Eucommiae Cortex* aqueous (EC) and ethanolic (ECe) extracts, *Achyranthis Radix* aqueous (AR) and ethanolic (ARe) extracts on the primary cultured rat articular chondrocytes.

Methods : MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium Bromide) assay was performed cytotoxic effect of test substances. In addition, anti-inflammatory effects were also observed on the lipopolysaccharide (LPS) treated chondrocytes through prostaglandin E₂ (PGE₂) production and 5-lipoxygenase (LPO) activities, and inhibitory effects on metalloproteinase (MMP)-2 and MMP-9 activities were observed on the recombinant human interleukin (rhIL)-1 α treated chondrocytes with their extracellular matrix (ECM) related mRNA expressions - collagen type II, SOX9 and aggrecan.

Results : As results, ECe and ARe showed obvious cytotoxicity against primary cultured rat articular chondrocytes at a dose level of 10 mg/ml, respectively. However, no obvious cytotoxic effects of PCP, EC and AR were demonstrated at a dose level of 10 mg/ml, on the primary cultured rat articular chondrocytes. In addition, treatment of LPS 50 μ g/ml induced significant increases of PGE₂ contents and 5-LPO activities indicating inflammatory responses of the primary cultured rat articular chondrocytes, and also decreases of cell viabilities, increases of MMP-2 and MMP-9 activities with decreases of extracellular matrix (ECM) related collagen type II, SOX9 and aggrecan mRNA expressions were observed by treatment of rhIL-1 α 50 ng/ml, suggesting damages on the primary cultured rat articular chondrocytes and related ECM degradations. However, these inflammatory responses and related ECM degradations were inhibited by pretreatment of all test substances, in order of PCP > ECe > ARe > EC > AR, and rhIL-1 α induced chondrocytes deaths are inhibited by treatment in order of PCP > EC > AR > ECe > ARe.

Conclusions : Taken together, it is expected that mixed formulation of PCP as main components with

• 접수 : 2017년 10월 18일 • 수정접수 : 2017년 11월 15일 • 채택 : 2017년 11월 20일

*These authors contributed equally to this work.

** 교신저자 : Young-Joon Lee, Department of Preventive medicine, College of Korean Medicine, Daegu Haany University,
1 Haanydaero, Gyeongsan, Gyeongsangbuk-Do, 38610, Republic of Korea

전화 : +82-53-819-1296, 팩스 : +82-53-819-1576, 전자우편 : gksxntk@dhu.ac.kr

Ki-Moon Park, Department of Foodscience and biotechnology, Sungkyunkwan University, 2066 Seoburo, Jangan-gu,
Suwon, Gyeonggi-do, 16419, Republic of Korea

전화 : +82-31-290-7806, 전자우편 : Pkm1001@skku.edu

appropriate proportion of EC and AR as additional components will be achieved a potent alternative medicinal food for osteoarthritis.

Key words : Primary cultured rat articular chondrocytes, Osteoarthritis, Dried pomegranate concentrate powders, *Eucommiae Cortex*, *Achyranthis Radix*, cytotoxicity

I. Introduction

Osteoarthritis (OA) is characterized by loss of articular cartilage components, mainly proteoglycans (PGs), leading to tissue destruction and hypocellularity, eventually resulting in loss of joint function¹. In particular, the proinflammatory cytokines have been shown to stimulate cartilage resorption and inhibit the synthesis of new matrix components in articular cartilage tissue^{2,3}. In addition, cytokines cause increases in prostaglandin E₂ (PGE₂) and nitric oxide release from chondrocytes^{4,5}, and reports have implicated both PGE₂ and nitric oxide involvement in the process of cartilage matrix turnover^{6,7}. Consequently, there is a pressing need to develop disease-modifying OA drugs⁸, and currently, the primary approach in the clinical treatment of OA involves the use of nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics and hyaluronan, which allow symptomatic relief, but provided no apparent disease-modifying effect⁹. In some instances, NSAIDs may even be deleterious effects; they inhibited the synthesis of PG, which play a crucial role in maintaining the function of the cartilage⁹. Therefore, there is a critical need to develop alternative agents that can prevent the destruction of cartilages or stimulate its proper repair. In these aspects, various efforts have been trialed that search for effective cartilage preserve agents through natural sources or mixed formulations with medicinal foods to achieve more potent anti-arthritis agents¹⁰⁻¹².

Pomegranate is a rich source of crude fibers,

pectin, sugars, and several tannins¹³. In addition, it has been reported that pomegranate contains some species of flavonoids and anthocyanidins in their seed oil and juice, and shows an antioxidant activity three times more potently than red wine and green tea extract^{14,15}. Furthermore, the powerful and favorable chondrocytes protective effects of pomegranate through their potent antioxidant and anti-inflammatory effects have been warranted, recently¹⁶⁻¹⁹. *Eucommiae Cortex* is a dried stem bark of *Eucommia Ulmoides* Oliver (*Eucommiaceae*), and has been used as a top-grade medicine in Korean medicine for antihypertensive, anti-inflammatory, antiviral, invigorating the kidney and hepatoprotective activities without side effects²⁰⁻²². Particularly, anti-arthritis effects of *Eucommiae Cortex* also reported, as component of mixed herbal formulations^{23,24}. *Achyranthis Radix*, a dried root part of *Achyranthes bidentata* Blume, is an important traditional Korean medicine and is extensively used by Korean medicine practitioners for the treatment of osteodynia of the lumbar region and knees, spasm and flaccidity of limbs²⁵. In particular, anti-arthritis effects of *Achyranthis Radix* also well-documented through various in vivo and in vitro experiments^{26,27}. Since appropriated mixed formulations of medicinal agents have been showed synergic elevation of biological activities on various diseases through diversity of their ingredients²⁸⁻³², it therefore, expected that appropriated mixed formulations with dried pomegranate concentrate powders and extracts of *Eucommiae Cortex* and *Achyranthis Radix* will be achieved more potent alternative agents

for osteoarthritis.

II. Materials and methods

1. Primary cultures of normal rat articular chondrocytes

Rat articular chondrocytes for primary culture were isolated from the knee joints of SPF/VAF Outbred CrI:CD1[SD, Sprague-Dawley] male rats (6-week-old upon receipt, body weight ranges 160~180 g; OrientBio, Seungnam, Korea) after 14 days of acclimatization. Cartilage was washed in phosphate-buffered saline (PBS) and finely minced into pieces measuring about 1-3 mm³. The cartilage tissue was digested for 0.5 h with 0.2% pronase (Sigma-Aldrich, St Louis, MO, USA), and then digested for 4 h with 0.1% collagenase (Sigma-Aldrich, St Louis, MO, USA) at 37°C. After collection of individual cells by brief centrifugation, the cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with antibiotic-antimycotic solution (100 U/mL penicillin, 100 mg/mL streptomycin and 0.25 mg/mL amphotericin B; Life Technologies, Carlsbad, CA, USA). The medium was replaced every 2 days, and the cells were incubated at 37°C under a humidified 5% CO₂ atmosphere. Cells within 5 passage times were used in this experiment. All laboratory animals were treated according to the national regulations of the usage and welfare of laboratory animals by the Institutional Animal Care and Use Committee in Daegu Haany University during acclimatization and sacrifice [Approval No. DHU2014-052].

2. Test materials

The dried pomegranate concentrate powders (PCP; ASYA Meyve Suyu ve Gıda San. A.Ş., Ankara, Turkey) contains 1.15 mg/g ellagic acid

as an active ingredient, the *Eucommiae Cortex* aqueous extract (EC) contained 1.62 mg/g pinore-sinol diglucoside, the *Achyranthis Radix* aqueous extract (AR) contained 0.25 mg/g ecdysterone, the *Eucommiae Cortex* ethanolic extract (ECe) contained 2.11 mg/g pinoresinol diglucoside and the *Achyranthis Radix* ethanolic extract (ARe) contained 1.06 mg/g ecdysterone (HL Science Co., Ltd., Anyang, Korea). Lipopolysaccharide (LPS; Sigma-Aldrich, St. Louise, MO, USA) and recombinant human interleukin (rhIL)-1 α (eBio-science, San Diego, CA, USA) were used to induce the inflammatory response and for degradation and cytotoxicity.

3. Cell viability assay of rat articular chondrocytes

Primary cultured rat articular chondrocytes were seeded in 24-well plates at a density of 2×10^4 cells/well and incubated in a CO₂ incubator at 37°C with 24-h samples (PCP, EC, AR, ECe and ARe at 10 mg/ml concentration) with/without 5 ng/ml rhIL-1 α (at 1 h after test substance treatment) before being treated with 100 μ l of 2.5 mg/ml MTT (Sigma-Aldrich, St. Louise, MO, USA). Then, the cells were incubated at 37°C for an additional 4 h. After checking production of MTT formazan, 1 ml of DMSO was added, and absorbance was read at 570 nm using a microplate reader (Sunrise; Tecan, Männedorf, Switzerland).

4. Detection of PGE₂ level and 5-LPO and MMP activities in chondrocytes

Primary cultured rat articular chondrocytes were seeded in 24-well plates at a density of 2×10^4 cells/well. The cells were grown in a CO₂ incubator at 37°C with 24-h samples (PCP, EC, AR, ECe and ARe at 1 mg/ml concentration) containing 50 μ g/ml LPS (for PGE₂ production and 5-LPO activity; at 1 h after test substance treatment)

or 5 ng/ml rhIL-1 α (for MMP activities; at 1 h after test substance treatment). PGE₂ level and 5-LPO, MMP-2, and MMP-9 activities in the supernatants were measured using the PGE₂ assay kit (R&D Systems, Minneapolis, MN, USA), the Lipoxygenase Inhibitor Screening Assay kit (Cayman Chemical, Ann Arbor, MI, USA) and a MMP enzyme-linked immunosorbent assay kit (Mybiosource, San Diego, CA, USA) with a microplate reader (Sunrise; Tecan, Männedorf, Switzerland) according to the manufacturer's protocol, as reported previously¹²⁾.

5. mRNA expression of extracellular matrix (ECM)-related chondrogenic genes in chondrocytes

Primary cultured rat articular chondrocytes were seeded in 24-well plates at a density of 5×10^6 cells/well. The cells were incubated in a CO₂ incubator at 37°C with 24-h samples (PCP, EC, AR, ECe and ARe at 1 mg/ml concentration) containing 5 ng/ml rhI-1 α (at 1 h after test substance treatment). Collagen type II, SOX9, and aggrecan mRNA expression levels were detected on the harvested cells by reverse transcription-polymerase chain reaction analysis according to previously established methods^{11,12)}. Briefly, RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA). The RNA concentrations and quality were determined with the CFX96™ Real-Time System (Bio-Rad, Hercules, CA, USA). RNA was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. The analysis was carried out using the ABI Step One Plus Sequence Detection System (Applied Biosystems,

Foster City, CA, USA), and expression levels were calculated relative to those of the vehicle control. Expression of β -actin mRNA was used as a control for tissue integrity in all samples. The sequences of the PCR oligonucleotide primers were as follows: 1) Collagen type II, F: 5'-GAG-TGGAAGAGCGGAGACTACTG-3', and R: 5'-CT-CCATGTTGCAGAAGACTTTCA-3'; 2) SOX9, F: 5'-AGAGCGTTGCTCGGAACTGT-3', and R: 5'-TC-CTGGACCGAAACTGGTAAA-3'; 3) Aggrecan, F: 5'-GATGTCCCTGCAATTACCA-3', and R: 5'-TCTGTGCAAGTGATTCGAGG-3'; 4) β -actin, F: 5'-ATCGTGGGCCGCCCTAGGCA-3', and R: 5'-TGGCCTTAGGGTTCAGAGGGG-3'.

6. Statistical analyses

All data were expressed as mean \pm SD of the 6 independent experiments. Multiple comparison tests were conducted for the group receiving different doses. The homogeneity of variance was examined using the Levene test. When the Levene test indicated no significant deviations from the homogeneity of the variance, the data were analyzed by one-way analysis of variance followed by the least-significant difference multi-comparison test to identify the significantly different member of a pair. The non-parametric Kruskal-Wallis H test was performed on data with a heterogeneous variance. When a significant difference was detected by the Kruskal-Wallis H test, the Mann-Whitney U-test with Bonferroni's correction was used to determine the specific pairs that differed. Statistical analyses were conducted using SPSS for Windows (Ver. 14.0 Korean edition, SPSS Inc., Chicago, IL, USA). Differences were considered significant at $P < 0.05$.

III. Results

1. Cytotoxic and cytoprotective effects of PCP, EC, and AR on normal primary cultured rat articular chondrocytes

Significant decreases in cell viability were detected in ECe- and ARe-treated chondrocytes

at 10 mg/ml, but no changes were demonstrated in PCP-, EC-, or 10 mg/ml AR-treated cells (Fig. 1). Cell viability was decreased significantly in rats treated with 5 ng/ml rhIL-1 α compared to the untreated vehicle controls, but rhIL-1 α treatment-related cell death was significantly inhibited by pretreatment with all five test substances (Fig. 2).




Figure 1. Effects on the normal primary cultured rat articular chondrocyte viabilities. Significant decreases of cell viabilities were detected in ECe and ARe treated chondrocytes at a concentration level of 10 mg/ml, but no meaningful changes on the cell viabilities were demonstrated in PCP, EC and AR 10 mg/ml concentration treated cells as compared with non-treated vehicle control after 24 h after incubation time. Values are expressed mean \pm SD of six independent experiments, AR = Aqueous extracts of *Achyranthis Radix*; ARe = Ethanolic extracts of *Achyranthis Radix*; EC = Aqueous extracts of *Eucommiae Cortex*; ECe = Ethanolic extracts of *Eucommiae Cortex*; PCP = Pomegranate Concentration Powder. * $p < 0.05$ as compared with control.




Figure 2. Cytoprotection effect on rhIL-1 α -treated chondrocytes. Significant decreases of cell viabilities were detected after treatment of rhIL-1 α 5 ng/ml as compared with non-treated vehicle control, but these rhIL-1 α treatment related cell deaths were significantly inhibited by pretreatment of all five test substances, in order of PCP > EC > AR > ECe > ARe. Values are expressed mean \pm SD of six independent experiments, AR = Aqueous extracts of *Achyranthis Radix*; ARe = Ethanolic extracts of *Achyranthis Radix*; EC = Aqueous extracts of *Eucommiae Cortex*; ECe = Ethanolic extracts of *Eucommiae Cortex*; PCP = Pomegranate Concentration Powder; rhIL = Recombinant human interleukin. * $p < 0.05$ as compared with vehicle control; $\dagger\dagger p < 0.01$ as compared with rhIL-1 α treated control.

2. Inhibitory effects of PCP, EC, and AR on PGE₂ productions

Marked and significant elevations of PGE₂ contents were observed after treatment of LPS 50 µg/ml as compared with non-treated vehicle control, but these LPS treatment related PGE₂ production elevations were significantly inhibited

by pretreatment of all five test substances, in order of PCP > ECe > ARe > EC > AR (Fig 3).

3. Inhibitory effects of PCP, EC, and AR on 5-LPO activities

Significant increases of 5-LPO activities were observed after treatment of LPS 50 µg/ml as




Figure 3. Inhibitory effects on PGE₂ productions. Marked and significant elevations of PGE₂ contents were observed after treatment of LPS 50 µg/ml as compared with non-treated vehicle control, but these LPS treatment related PGE₂ production elevations were significantly inhibited by pretreatment of all five test substances, in order of PCP > ECe > ARe > EC > AR. Values are expressed mean ± SD of six independent experiments. AR = Aqueous extracts of *Achyranthis Radix*; ARe = Ethanolic extracts of *Achyranthis Radix*; EC = Aqueous extracts of *Eucommiae Cortex*; ECe = Ethanolic extracts of *Eucommiae Cortex*; PCP = Pomegranate Concentration Powder; PGE₂ = Prostaglandin E₂; LPS = Lipopolysaccharide. ** $p < 0.01$ and * $p < 0.05$ as compared with vehicle control; †† $p < 0.01$ as compared with LPS treated control.




Figure 4. Inhibitory effects on 5-LPO activities. Significant increases of 5-LPO activities were observed after treatment of LPS 50 µg/ml as compared with non-treated vehicle control, but these LPS treatment related increases of 5-LPO activities were also significantly inhibited by pretreatment of all five test substances, in order of PCP > ECe > ARe > EC > AR. Values are expressed mean ± SD of six independent experiments. AR = Aqueous extracts of *Achyranthis Radix*; ARe = Ethanolic extracts of *Achyranthis Radix*; EC = Aqueous extracts of *Eucommiae Cortex*; ECe = Ethanolic extracts of *Eucommiae Cortex*; PCP = Pomegranate Concentration Powder; LPO = Lipoxygenase; LPS = Lipopolysaccharide. ** $p < 0.01$ and * $p < 0.05$ as compared with vehicle control; †† $p < 0.01$ as compared with LPS treated control.

compared with non-treated vehicle control, but these LPS treatment related increases of 5-LPO activities were also significantly inhibited by pretreatment of all five test substances, in order of PCP > ECe > ARe > EC > AR, in the current experiment (Fig 4).

4. Inhibitory effects of PCP, EC, and AR on MMP-2 and MMP-9 activities

MMP-2 and MMP-9 activities increased significantly in rats treated with 5 ng/ml rhIL-1 α compared with in untreated vehicle controls, but these increases in MMP-2 and MMP-9 activities were also significantly inhibited by pretreatment with all five test substances in the order of PCP > ECe > ARe > EC > AR (Fig 5).

5. Up-regulation ECM related chondrogenic gene mRNA expressions

The mRNA expression levels of ECM-related chondrogenic genes, such as collagen type II, SOX9, and aggrecan, decreased significantly in

rats treated with 5 ng/ml rhIL-1 α compared with in untreated vehicle controls, but mRNA expression was significantly upregulated after pretreatment with all five test substances in the order of PCP > ECe > ARe > EC > AR (Fig 6).

IV. Discussion

In this experiment, ECe and ARe showed obvious cytotoxicity against primary cultured rat articular chondrocytes at a dose level of 10 mg/ml. However, no obvious cytotoxic effects of PCP, EC and AR were demonstrated at a dose level of 10 mg/ml. In addition, similar to those of previous reports by other investigators^{11,12)}, treatment of LPS 50 μ g/ml induced significant increases of PGE₂ contents and 5-LPO activities indicating inflammatory responses of the primary cultured rat articular chondrocytes, and also decreases of cell viabilities, increases of MMP-2 and MMP-9 activities with decreases of ECM related collagen type II, SOX9 and aggrecan mRNA expressions were observed by treatment of rhIL-1 α 50 ng/ml,




Figure 5. Inhibitory effects on (A) MMP-2 and (B) MMP-9 activities. Dramatic increases of MMP-2 and MMP-9 activities were observed after treatment of rhIL-1 α 5 ng/ml as compared with non-treated vehicle control, but these rhIL-1 α treatment related increases of MMP-2 and MMP-9 activities were also significantly inhibited by pretreatment of all five test substances, in order of PCP > ECe > ARe > EC > AR. Values are expressed mean \pm SD of six independent experiments, AR = Aqueous extracts of *Achyranthis Radix*; ARe = Ethanolic extracts of *Achyranthis Radix*; EC = Aqueous extracts of *Eucommiae Cortex*; ECe = Ethanolic extracts of *Eucommiae Cortex*; PCP = Pomegranate Concentration Powder; MMP = Matrix metalloproteinase; rhIL = Recombinant human interleukin. ** $p < 0.01$ as compared with vehicle control; †† $p < 0.01$ as compared with rhIL-1 α treated control.




Figure 6. Effects on (A) Collagen Type II, (B) SOX9, and (C) aggrecan mRNA expressions. Noticeable and significant decreases of collagen type II, SOX9, and aggrecan mRNA expressions were observed after treatment of rhIL-1α 5 ng/ml as compared with non-treated vehicle control, but these decreases of mRNA expressions were significantly up-regulated by pretreatment of all five test substances, in order of PCP > ECe > ARe > EC > AR. Values are expressed mean ± SD of six independent experiments. AR = Aqueous extracts of *Achyranthis Radix*; ARe = Ethanolic extracts of *Achyranthis Radix*; EC = Aqueous extracts of *Eucommiae Cortex*; ECe = Ethanolic extracts of *Eucommiae Cortex*; PCP = Pomegranate Concentration Powder; rhIL = Recombinant human interleukin. ** $p < 0.01$ as compared with vehicle control; †† $p < 0.01$ and † $p < 0.05$ as compared with rhIL-1α treated control.

suggesting damages on the primary cultured rat articular chondrocytes and related ECM degradations. However, these inflammatory damages of chondrocytes and related ECM degradations induced by treatment of LPS or rhIL-1α were inhibited by pretreatment of all five test substance at a dose level of 1 mg/ml, in order of PCP > ECe > ARe > EC > AR, except for cell viability; rhIL-1α induced chondrocytes deaths are inhibited by treatment of PCP > EC > AR > ECe > ARe in that orders.

In MTT assay, favorable osteoarthritis control agent should be showed lower cytotoxic effects on normal chondrocytes, and can be protect the

physical and inflammatory response related chondrocyte deaths and damages^{11,12)}. In the present study, significant decreases of cell viabilities were detected in ECe and ARe treated chondrocytes at a concentration level of 10 mg/ml, but no meaningful changes on the cell viabilities were demonstrated in PCP, EC and AR 10 mg/ml concentration treated cells as compared with non-treated vehicle control after 24 hrs after incubation time. In addition, rhIL-1α treatment related cell deaths were significantly inhibited by pretreatment of all five test substances, in order of PCP > EC > AR > ECe > ARe. These are considered that all test substances have favorable

cytoprotection effects on the chondrocyte damages induced by inflammatory stresses.

Metabolism of arachidonic acid has been regarded as critical mechanisms that regulated the body homeostasis, as part of inflammatory processes; it involved in the synthesis of prostaglandins - chemical mediator of inflammation and leukotriene - chemical mediator to regulate immune responses including inflammatory, asthmatic and allergic responses³³. 5-Lipoxygenase (5-LPO) is an enzyme that involved in biosynthesis of leukotriene³⁴, and PGE₂ was produced by other enzyme, cyclooxygenase (COX)-2 coordination with IL-1 and tumor necrosis factor (TNF)- α and involved in etiopathogenesis of osteoarthritis, the degradation of articular cartilages^{35,36}. In addition, PGE₂ also induced abnormal bone growth and painful osteophytes, which were frequently encountered in the patients suffering from osteoarthritis^{12,37}. In the present study, anti-inflammatory potentials of test substances were observed through PGE₂ productions and 5-LPO activities on the LPS treated primary cultured rat articular chondrocytes.

Important enzymes involved in deconstruction of chondrocyte and bony tissue, are proteolytic enzymes, MMPs, and they were inhibited by tissue inhibitor of metalloproteinases system at normal conditions³⁸. Since MMPs act as protease that degraded the ECM, mainly PGs³⁹, they have been regarded as a valuable treatment target in osteoarthritis^{11,40}. As results of the present study, the rhIL-1 α treatment related increases of MMP-2 and MMP-9 activities were also significantly inhibited by pretreatment of all five test substances, in order of PCP > ECe > ARe > EC > AR, suggesting their powerful MMP-2 and MMP-9 inhibitory effects, and related chondrocyte protective effects, at least in a part of the possibilities of anti-arthritic effects.

It has been believed that degradations of ECM such as collagen type II, aggrecan and SOX9 from the results of inflammation related chondrocyte

deaths and damages are involved in the deterioration of the homeostasis and articular functional limitations in osteoarthritis⁴¹. In this study, the decreases of collagen type II, SOX9 and aggrecan mRNA expressions, induced by rhIL-1 α treatment, were significantly up-regulated by pretreatment of all five test substances, in order of PCP > ECe > ARe > EC > AR. These findings are considered that all test materials have favorable articular cartilage preserve effects, through enhancement of ECM production of chondrocytes.

Since this study was conducted under *in vitro* conditions, it is a limitation that these research results are not applied to *in vivo* condition directly, so additional researches are needed to evaluate the efficacy in animal disease model.

V. Conclusion

Taken together the results of this experiment, it is expected that mixed formulation of PCP as main components with appropriate proportion of EC and AR as additional components will be achieved a potent medicinal food for osteoarthritis, through further animal experiments.

Acknowledgement

This research was supported by the Foundation of Agri. Tech, Commercialization & Transfer (FACT) through the R & D Results Commercialization Support Project (NO. PJ011566) on 2015.

References

1. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. *Arthritis Rheum.* 1998;41(8):1343-1355.
2. Goldring MB, Fukuo K, Birkhead JR, Dudek E, Sandell LJ. Transcriptional suppression

- by interleukin-1 and interferon-gamma of type II collagen gene expression in human chondrocytes. *J Cell Biochem*. 1994;54(1):85-99.
3. van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor α , and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. *Arthritis Rheum*. 1995;38(2):164-172.
 4. Berenbaum F, Jacques C, Thomas G, Corvol MT, Bereziat G, Masliah J. Synergistic effect of interleukin-1b and tumor necrosis factor α on PGE₂ production by articular chondrocytes does not involve PLA₂ stimulation. *Exp Cell Res*. 1996;222(2):379-384.
 5. Grabowski PS, Macpherson H, Ralston SH. Nitric oxide production in cells derived from the human joint. *Br J Rheumatol*. 1996;35(3):207-212.
 6. Stefanovic-Racic M, Morales TI, Taskiran D, McIntyre LA, Evans CH. The role of nitric oxide in proteoglycan turnover by bovine articular cartilage organ cultures. *J Immunol*. 1996;156(3):1213-1220.
 7. Koolpe M, Pearson D, Benton HP. Expression of both P₁ and P₂ purine receptor genes by human articular chondrocytes and profile of ligand-mediated prostaglandin E₂ release. *Arthritis Rheum*. 1999;42(2):258-267.
 8. Appleton CT, McErlain DD, Pitelka V, Schwartz N, Bernier SM, Henry JL, Holdsworth DW, Beier F. Forced mobilization accelerates pathogenesis: characterization of a preclinical surgical model of osteoarthritis. *Arthritis Res Ther*. 2007;9(1):R13.
 9. Tamura T, Ohmori K. Rhein, an active metabolite of diacerein, suppresses the interleukin-1 α -induced proteoglycan degradation in cultured rabbit articular chondrocytes. *Jpn J Pharmacol*. 2001;85(1):101-104.
 10. Qin J, Liu YS, Liu J, Li J, Tan Y, Li XJ, Magdalou J, Mei QB, Wang H, Chen LB. Effect of *Angelica sinensis* Polysaccharides on Osteoarthritis *In Vivo* and *In Vitro*: A Possible Mechanism to Promote Proteoglycans Synthesis. *Evid Based Complement Alternat Med*. 2013;2013:794761.
 11. Na JY, Song KB, Kim SH, Kwon YB, Kim DG, Lee JK, Jo HK, Kwon JK. Effects of HPL-04 on degenerative osteoarthritis. *J Korean Soc Food Sci Nutr*. 2014;43(1):30-39.
 12. Nam DE, Kim OK, Shim TJ, Kim JH, Lee JM. Effect of *Boswellia serrata* extracts on degenerative osteoarthritis *in vitro* and *in vivo* models. *J Korean Soc Food Sci Nutr*. 2014;43(5):631-640.
 13. Gil MI, Tomás-Barberán FA, Hess-Pierce B, Holcroft DM, Kader AA. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. *J Agric Food Chem*. 2000;48(10):4581-4589.
 14. Noda Y, Kaneyuki T, Mori A, Packer L. Antioxidant activities of pomegranate fruit extract and its anthocyanidins: delphinidin, cyanidin, and pelargonidin. *J Agric Food Chem*. 2002;50(1):166-171.
 15. Singh RP, Chidambara Murthy KN, Jayaprakasha GK. Studies on the antioxidant activity of pomegranate (*Punica granatum*) peel and seed extracts using in vitro models. *J Agric Food Chem*. 2002;50(1):81-86.
 16. Ahmed S, Wang N, Hafeez BB, Cheruvu VK, Haqqi TM. *Punica granatum L.* extract inhibits IL-1b-induced expression of matrix metalloproteinases by inhibiting the activation of MAP kinases and NF-kB in human chondrocytes in vitro. *J Nutr*. 2005;135(9):2096-2102.
 17. Shukla M, Gupta K, Rasheed Z, Khan KA, Haqqi TM. Bioavailable constituents/metabolites of pomegranate (*Punica granatum L*) preferentially inhibit COX2 activity *ex vivo*

- and IL-1 β -induced PGE2 production in human chondrocytes *in vitro*. *J Inflamm* 2008; 5:9.
18. Hadipour-Jahromy M, Mozaffari-Kermani R. Chondroprotective effects of pomegranate juice on monoiodoacetate-induced osteoarthritis of the knee joint of mice. *Phytother Res*. 2010;24(2):182-185.
 19. Rasheed Z, Akhtar N, Haqqi TM. Pomegranate extract inhibits the interleukin-1 β -induced activation of MKK-3, p38 α -MAPK and transcription factor RUNX-2 in human osteoarthritis chondrocytes. *Arthritis Res Ther*. 2010;12(5):R195.
 20. Hsieh CL, Yen GC. Antioxidant actions of du-zhong (*Eucommia ulmoides* Oliv.) toward oxidative damage in biomolecules. *Life Sci*. 2000;66(15):1387-1400.
 21. Kwan CY, Chen CX, Deyama T, Nishibe S. Endothelium-dependent vasorelaxant effects of the aqueous extracts of the *Eucommia ulmoides* Oliv. leaf and bark: implications on their antihypertensive action. *Vascul Pharmacol*. 2003;40(5):229-235.
 22. Zhao Y, Li Y, Wang X, Sun W. The experimental study of *Cortex Eucommiae* on meridian tropism: the distribution study of aucubin in rat tissues. *J Pharm Biomed Anal*. 2008;46(2):368-373.
 23. Eum HA, Lee WY, Kim SH, Kim JY, Park SW, Lee JS, Choi SM, Pyo S, Kang MJ, Min YD, Shim SH, Shin DH, Lee SM. Anti-inflammatory activity of CML-1: an herbal formulation. *Am J Chin Med*. 2005;33(1):29-40.
 24. Lee SY, Kwon HK, Lee SM. SHINBARO, a new herbal medicine with multifunctional mechanism for joint disease: first therapeutic application for the treatment of osteoarthritis. *Arch Pharm Res*. 2011;34(11):1773-1777.
 25. Li J, Li HJ, Li P, Qi H. Simultaneous qualification and quantification of four phytoecdysones in Radix *Achyranthis Bidentatae* by high-performance liquid chromatography with diode array detection. *Biomed Chromatogr*. 2007;21(8):823-828.
 26. Yu F, Li X, Cai L, Li H, Chen J, Wong X, Xu H, Zheng C, Liu X, Ye H. *Achyranthes bidentata* polysaccharides induce chondrocyte proliferation via the promotion of the G₁/S cell cycle transition. *Mol Med Rep*. 2013;7(3):935-940.
 27. Weng X, Lin P, Liu F, Chen J, Li H, Huang L, Zhen C, Xu H, Liu X, Ye H, Li X. *Achyranthes bidentata* polysaccharides activate the Wnt/b-catenin signaling pathway to promote chondrocyte proliferation. *Int J Mol Med*. 2014;34(4):1045-1050.
 28. Lee HS, Kim HH, Ku SK. Hepatoprotective effects of *Artemisiae capillaris herba* and *Picrorrhiza rhizoma* combinations on carbon tetrachloride-induced subacute liver damage in rats. *Nutr Res*. 2008;28(4):270-277.
 29. Choi JS, Kim JW, Kim KY, Cho HR, Choi IS, Ku SK. Antiosteoporotic effects of Polycan in combination with calcium lactate-gluconate in ovariectomized rats. *Exp Ther Med*. 2014; 8(3):957-967.
 30. Choi JS, Kim JW, Kim KY, Lee JK, Sohn JH, Ku SK. Synergistic effect of fermented rice extracts on the probiotic and laxative properties of yoghurt in rats with loperamide-induced constipation. *Evid Based Complement Alternat Med*. 2014;2014:878503.
 31. Choi JS, Shin HS, Kim KY, Ku SK, Choi IS, Kim JW. Effect of Polycalcium, a mixture of Polycan and calcium lactate-gluconate in a 1:9 weight ratio, on rats with surgery-induced osteoarthritis. *Exp Ther Med*. 2015;9(5):1780-1790.
 32. Kang SJ, Choi BR, Kim SH, Yi HY, Park HR, Kim DC, Choi SH, Han CH, Park SJ, Song CH, Ku SK, Lee YJ. Dried pomegranate potentiates anti-osteoporotic and anti-obesity

- activities of red clover dry extracts in ovariectomized rats. *Nutrients*. 2015;7(4):2622–2647.
33. Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. *Biochem Biophys Res Commun*. 1997;235(2):418–423.
34. Sailer ER, Schweizer S, Boden SE, Ammon HP, Safayhi H. Characterization of an acetyl-11-keto- β -boswellic acid and arachidonate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling. *Eur J Biochem*. 1998;256(2):364–368.
35. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. *Annu Rev Pharmacol Toxicol*. 1998;38:97–120.
36. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. *Mayo Clin Proc*. 1999;74(11):1095–1105.
37. Hardy MM, Seibert K, Manning PT, Currie MG, Woerner BM, Edwards D, Koki A, Tripp CS. Cyclooxygenase 2-dependent prostaglandin E_2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. *Arthritis Rheum*. 2002;46(7):1789–1803.
38. Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. *J Rheumatol*. 1999;26(3):717–719.
39. Nagase H, Woessner JF, Jr. Matrix metalloproteinases. *J Biol Chem*. 1999;274(31):21491–21494.
40. Halliwell B. Oral inflammation and reactive species: a missed opportunity? *Oral Dis*. 2000;6(3):136–137.
41. Guzman RE, Evans MG, Bove S, Morenko B, Kilgore K. Mono-iodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis. *Toxicol Pathol*. 2003;31(6):619–624.